Ellie Merle | BiotechTV

top of page

Barclays Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO

She says that consensus is a hazard ratio of 0.6 and that degrees of success could be viewed whether the data comes in lower or higher than that.

Bright Minds

Oct 21

Barclays Miami: Barclays' Senior Biotech Analyst Ellie Merle shares her take on biotech and thoughts on companies she covers that have been in the news

She discusses uniQure, Moderna, BridgeBio, Gossamer Bio and more. Chapters General take on biotech - 0:36 uniQure - 1:43 Moderna - 4:34 BridgeBio - 7:04 Gossamer Bio - 8:07 Other catalysts - 9:36

Bright Minds

Mar 10

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

Learn more

bottom of page

Barclays Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO

Barclays Miami: Barclays' Senior Biotech Analyst Ellie Merle shares her take on biotech and thoughts on companies she covers that have been in the news

Follow BiotechTV

Sponsors

Sponsor Spotlight